Nuvectis Pharma (NVCT) Retained Earnings (2021 - 2026)
Nuvectis Pharma (NVCT) posted Retained Earnings of -$105.7 million for Q1 2026, down 189.5% sequentially from $118.1 million in Q4 2025, and down 34.52% YoY from -$161.4 million in Q1 2025.
Nuvectis Pharma (NVCT) Retained Earnings (2021 - 2026) Analysis & Trends
Nuvectis Pharma has reported Retained Earnings for 6 years, with the latest figure at -$105.7 million in Q1 2026.
- Quarterly Retained Earnings fell 34.52% year-over-year to -$105.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$105.7 million (down 34.52% YoY) and the FY2025 annual result came in at $118.1 million, up 261.24% from the prior year.
- Retained Earnings declined to -$105.7 million in Q1 2026 per NVCT's latest filing, from $118.1 million in the prior quarter.
- Over five years, Retained Earnings peaked at $118.1 million in Q4 2025 and troughed at -$105.7 million in Q1 2026.
- A 5-year average of -$27.3 million and a median of -$41.7 million in 2023 frame the typical range for Retained Earnings.
- The sharpest annual moves came in 2022 and 2024: Retained Earnings slumped 1790.54% in 2022, then jumped 301.22% in 2024.
- Over 5 years, Retained Earnings stood at -$32.0 million in 2022, then sank by 69.6% to -$54.2 million in 2023, then plunged by 35.03% to -$73.2 million in 2024, then surged by 261.24% to $118.1 million in 2025, then plunged by 189.5% to -$105.7 million in 2026.
- According to Business Quant data, Retained Earnings over the past three periods registered -$105.7 million, $118.1 million, and -$92.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 15.69 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 37.62 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -4.00 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 13.05 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -104.13 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 4.38 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -6.33 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 6.57 Bn |
| 10 | Nuvectis Pharma | 506.13 Mn | 506.13 Mn | - | 121.84 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 121.84 Mn |
| Mar 31, 2026 | -105.70 Mn |
| Dec 31, 2025 | 118.10 Mn |
| Sep 30, 2025 | -92.37 Mn |
| Jun 30, 2025 | -84.90 Mn |
| Mar 31, 2025 | -78.58 Mn |
| Dec 31, 2024 | -73.25 Mn |
| Sep 30, 2024 | -67.00 Mn |
| Jun 30, 2024 | -62.84 Mn |
| Mar 31, 2024 | 72.44 Mn |
| Dec 31, 2023 | -54.25 Mn |
| Sep 30, 2023 | 64.31 Mn |
| Jun 30, 2023 | -41.74 Mn |
| Mar 31, 2023 | -36.00 Mn |
| Dec 31, 2022 | -31.99 Mn |
| Sep 30, 2022 | 45.66 Mn |
| Jun 30, 2022 | -19.40 Mn |
| Mar 31, 2022 | -15.80 Mn |
| Dec 31, 2021 | 1.89 Mn |